Report

Global drug delivery systems market is projected to witness a CAGR of 9.14% during the forecast period 2024-2031, growing from USD 151.6 billion in 2023 to USD 305.19 billion in 2031. The dynamics shaping the global drug delivery systems market encompass a spectrum of elements, such as the escalation of chronic diseases, the surge in demand for self-administration devices, advancements in technology, the growth of the geriatric population, the prominence of biologics and large molecule drugs, increased investment, collaborative partnerships, the burgeoning market in emerging economies, supportive regulatory frameworks, and the advent of personalized medicine.
The global drug delivery systems market is in a phase of significant transformation, driven by a diverse range of influential factors. The escalating incidence of chronic diseases, such as cancer, diabetes, and cardiovascular conditions, serve as a pivotal force, stimulating the need for more efficient and targeted drug delivery methods. Concurrently, there's a notable surge in patient preference for self-administration tools, aiming for convenience and self-management in their therapies. Furthermore, the continual advancement of technology assumes a crucial role in enhancing drug delivery systems. Additionally, the increasing elderly population, with its unique healthcare requirements, underscores the demand for tailor-made delivery systems designed specifically for older individuals in the global drug delivery systems market.
The global drug delivery systems market configuration is further influenced by the prominence of biologics and large molecule drugs, necessitating sophisticated delivery platforms to ensure efficient administration. Collaborative alliances between pharmaceutical firms and research institutions drive innovation, accelerating the creation and commercialization of pioneering delivery systems. Concurrently, the burgeoning healthcare markets in developing economies present unexplored avenues for expansion, buoyed by supportive regulatory frameworks that facilitate research and development ventures. The emergence of personalized medicine, focused on customized therapies tailored to individual patient needs, signifies a substantial shift, fueling the quest for personalized drug delivery solutions on a global scale and boosting the global drug delivery systems market.
Surge in Demand for Self-Administration Devices
The rising demand for self-administration devices is a key catalyst driving the global drug delivery systems market expansion. Patients increasingly desire independence and ease in handling their treatments, resulting in a noticeable uptick in the uptake of such devices. These self-administration solutions, including injectable pens, wearable technologies, and other user-friendly tools, grant patients' greater autonomy in managing their therapies, simplifying the treatment process. This upsurge mirrors a change in patient preferences and underscores a fundamental shift in healthcare delivery, highlighting the significance of personalized and convenient treatment choices. As a result, the market for drug delivery systems is experiencing substantial growth, fueled by the escalating preference for self-administration devices among healthcare consumers worldwide.
Increased Investments
Numerous corporations are reinforcing their financial commitments in the global drug delivery systems sector, demonstrated through the creation of fresh production facilities. This strategic endeavor entails the construction of cutting-edge sites geared towards manufacturing sophisticated drug delivery systems. By expanding their manufacturing prowess, firms endeavor to satisfy increasing market needs, pioneer inventive delivery approaches, and streamline production efficiency. These investments reflect a dedication to augment research, development, and production capabilities, enabling the companies to seize the burgeoning prospects within the ever-changing pharmaceutical arena.
For instance, in March 2023, Genixus, a firm dedicated to producing and creating drug delivery systems, declared the completion of a new manufacturing facility in Concord, N.C. The site is equipped with automated manufacturing and state-of-the-art technology specifically designed to bolster the KinetiX syringe platform and broaden its product range. This increase in manufacturing capability is a direct response to the market's call for ready-to-administer (RTA) syringes.
Government Initiatives
Governments globally are proactively executing various programs to nurture the expansion of the worldwide drug delivery systems market. These initiatives involve diverse approaches like incentivizing research and development, simplifying regulatory processes to hasten approvals, and offering financial aid or grants to spur innovation. Furthermore, certain governments are cultivating partnerships between educational institutions, industries, and research centers, easing the transfer of technology, and encouraging investments in sophisticated drug delivery technologies. These extensive actions reflect a unified endeavor to propel progress in drug delivery systems, aiming for enhanced treatments, improved patient results, and meeting evolving healthcare demands globally.
For example, in February 2021, the Union Cabinet of India approved the Production Linked Incentive (PLI) initiative tailored for the pharmaceutical sector. The scheme aims to elevate India's manufacturing capacities by augmenting investments and production within the sector, fostering the expansion of product diversity towards high-value pharmaceutical goods. Additionally, the scheme seeks to cultivate globally competitive entities in India, empowering them to expand in scope and magnitude by integrating advanced technology, thus enabling their integration into global value chains.
Growing demand for Autoinjectors
There's a notable increase in the global drug delivery systems market's interest in autoinjectors. These tools facilitate patient-friendly, self-administered medication, especially advantageous for individuals needing regular injections. The escalating incidence of chronic illnesses and the preference for home-based healthcare solutions play a role in driving this escalated need. Autoinjectors ensure accuracy in dosing, ease of use, and a decrease in medical mistakes, promoting patient adherence to treatments. Additionally, technological advancements, improvements in design, and the widening application of injectable medications in various therapeutic areas contribute to the growing acceptance of autoinjectors. Consequently, they emerge as a pivotal driver in the expansion of the drug delivery systems market.
For instance, in September 2023, Ypsomed, a Swiss medical technology firm, disclosed a prolonged supply agreement with Novo Nordisk for autoinjectors. This partnership highlights the advantageous impact of the Danish pharmaceutical company's weight-loss drug business on firms specializing in pharmaceutical services. Ypsomed plans to increase its production capacities in the upcoming years, with Novo Nordisk playing a substantial role by investing in the added production infrastructure.
Drug Delivery Systems for Diabetes
The escalating demand for drug delivery systems tailored for diabetes treatment significantly drives growth within the global drug delivery systems market. Diabetes, a prevalent chronic condition, requires consistent and precise medication administration. This heightened demand stems from the need for effective delivery mechanisms ensuring optimized drug dosing, improved patient compliance, and reduced treatment-associated complications. With advancements in diabetes management and the expansion of therapeutic options, the market experiences an upsurge in innovative drug delivery systems catering specifically to diabetic patients, thereby contributing substantially to the market's expansion and evolution.
For example, Terumo India, the Indian division of Terumo Corporation, a prominent global player in medical technology, unveiled an insulin syringe on November 14, 2023. This sterile delivery device caters to patients needing frequent insulin injections, elevating standards for patient comfort and adherence to therapy.
Future Market Scenario (2024-2031F)
The future prospects of the global drug delivery systems market display a high level of promise. Several factors contribute to this positive outlook, notably ongoing technological advancements that consistently refine drug delivery techniques. These innovations result in more accurate, targeted, and efficient medication administration, elevating treatment effectiveness, while reducing potential side effects. Moreover, the escalating prevalence of chronic diseases like cancer, diabetes, and cardiovascular ailments worldwide drives the demand for advanced drug delivery systems. This need is amplified by an increasingly aging population requiring specialized treatment modalities. Additionally, the industry's response to global health crises, such as the COVID-19 pandemic, has expedited research and development, yielding rapid progress in vaccine delivery methods and therapeutics. The continual expansion of healthcare infrastructure in emerging economies and the emphasis on personalized medicine further propels the ongoing evolution and potential expansion of the global drug delivery systems market.
Key Players Landscape and Outlook
The global drug delivery systems market is currently witnessing a series of acquisitions. These strategic moves involve companies acquiring or merging with other entities to expand their product portfolios, enhance market presence, or access novel technologies. Acquisitions offer opportunities for companies to consolidate their positions, capitalize on synergies, and gain competitive advantages. They facilitate access to new markets, diversification of offerings, and acceleration of innovation by integrating complementary expertise. These transactions signify a dynamic phase within the drug delivery systems industry, aimed at reinforcing market foothold and fostering growth through strategic partnerships and expansions.
For instance, in July 2023, Novartis, a Swiss multinational pharmaceutical corporation, completed the acquisition of DTx Pharma, a startup specializing in RNA medicine delivery, for $500 million. DTx Pharma's Fatty Acid Ligand Conjugated Oligonucleotide (FALCON) platform enables the delivery of siRNA therapeutics outside the liver.